Infectious disease
Peter Adams and Dave Harris at Rockies Venture Club (the oldest angel investment group in the U.S.) explored those myths and offered strategies to counter them.
Flu season is here and overall viral activity is up 23% across the United States, even as respiratory syncytial virus and COVID-19 infections continue to sweep across parts of the nation.
It proved itself superior to AZD1222 (ChAdOx1-S), the vaccine by Astrazeneca-Oxford, in terms of geometric mean titer for neutralization antibodies.
The concern relates to the risk of two rare heart inflammation conditions, myocarditis and pericarditis, that have been linked to the Pfizer and Moderna mRNA vaccines.
The advisory committee voted 19-0 to recommend the extra dose of the J&J shot for anyone 18 years and older.
Read about TFF Pharmaceuticals and Augmenta Bioworks’ dry powder COVID-19 antibody formula, the world’s first gene editing clinical trial for PKU, Bayer’s COVID-19 vaccine and other key developments in life sciences research.
It was yet another busy week for clinical trial announcements. Take a look.
The FDA and Regeneron are reportedly in talks to set up an advisory committee meeting to discuss the BLA ahead of the target action date.
Merck is getting its chance at participating in the pandemic. The FDA has announced an outside expert panel will meet on November 30 to deliberate on Merck’s COVID-19 pill.
The news of a unanimous decision by the adcom came just two days after the agency issued a 45-page document that contained vague comments on the drug.
PRESS RELEASES